{"id":390491,"date":"2019-01-22T00:00:00","date_gmt":"2019-01-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0026-2019-biopharma-alzheimers-disease-treatment-algorithms-claims-data-analysis-us-2019\/"},"modified":"2026-04-16T11:25:28","modified_gmt":"2026-04-16T11:25:28","slug":"algocg0026-2019-biopharma-alzheimers-disease-treatment-algorithms-claims-data-analysis-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0026-2019-biopharma-alzheimers-disease-treatment-algorithms-claims-data-analysis-us-2019\/","title":{"rendered":"Alzheimer&#8217;s Disease | Treatment Algorithms | Claims Data Analysis | US | 2019"},"content":{"rendered":"<p>For the estimated 3.4 million people in the United States who suffer from Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantine) that deliver modest efficacy of limited duration. Understanding today\u2019s treatment landscape is important for emerging players as the heavily generic\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0therapy market braces for the potential entry of a variety of new, high-cost brands\u2014namely, landmark disease-modifying therapies and new behavioral adjuncts. Our\u00a0<em>Treatment Algorithms: Claims Data Analysis\u00a0<\/em>content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients. A separate, companion claims data analysis offers a detailed look at the use of neuropsychiatric drugs used to treat\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0patients?<\/li>\n<li>How has Namzaric been integrated into the treatment algorithm?<\/li>\n<li>What proportion of\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?<\/li>\n<li>What percentage of\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated\u00a0<abbr title=\"Alzheimer's disease\">AD<\/abbr>\u00a0patients?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em>\u00a0provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so that you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States<\/p>\n<p><strong>Real-world data:\u00a0<\/strong>Longitudinal patient-level claims data analysis<\/p>\n<p><strong>Key companies:\u00a0<\/strong>Allergan, Novartis<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Donepezil, galantamine, rivastigmine, rivastigmine patch, memantine\u00a0<abbr title=\"immediate release\">IR<\/abbr>, Namenda\u00a0<abbr title=\"extended release\">XR<\/abbr>, Namzaric<\/p>\n<p><strong>Key analysis provided:<\/strong><\/p>\n<ul>\n<li>Brand\/therapy use across longitudinal patient sample.<\/li>\n<li>Newly diagnosed patient analysis.<\/li>\n<li>Treatment initiation and progression.<\/li>\n<li>Line of therapy analysis.<\/li>\n<li>Combination therapy analysis.<\/li>\n<li>Source of business for recently treated patients.<\/li>\n<li>Persistency and compliance analysis.<\/li>\n<li>Product-level patient flowcharts.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390491","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390491\/revisions"}],"predecessor-version":[{"id":393615,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390491\/revisions\/393615"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}